61Cu-NODAGA-LM3 PET/CT for the Detection of Neuroendocrine Tumors (COPPER PET in NET)

计划入组 27 人 · 首次发布于 2024 年 6 月 12 日

A Phase 2 Trial of 61Cu-NU101 PET/CT Compared Against Current Standard-of-care 18F-piflufolastat (Pylarify®) PET/CT.

计划入组 34 人 · 首次发布于 2026 年 6 月 9 日

A Phase I Trial of 61Cu-NODAGA-PSMA for Patients with Prostate Cancer

计划入组 8 人 · 首次发布于 2024 年 12 月 16 日

(61Cu)TraceNET

61Cu-based TraceNET radiodiagnostic(Nuclidium)

61Cu-NuriPro

TRANET HOLDINGS PTE. LTD.

Singapore

NUCLIDIUM's Copper-Based PET Tracer Shows Promise in Phase I/II Trial for Neuroendocrine Tumor Detection

NUCLIDIUM's Copper-Based Radiotracer Shows Enhanced Imaging Performance in First Prostate Cancer Patient

Nuclidium Raises $99M Series B to Advance Copper-Based Radiopharmaceutical Platform